An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA.
OBJECTIVE
To investigate the fitness of serum apolipoprotein M (apoM) concentration as a marker for maturity-onset diabetes of the young 3 (MODY3).


METHODS
This study consisted of two parts. A family study included 71 carriers of the P291fsinsC mutation in hepatocyte nuclear factor-1alpha (HNF-1alpha) from the Finnish Botnia study, 53 of whom were diabetic, and 75 matched family controls. A second, case-control study included 24 MODY3 patients, 17 healthy MODY3 mutation carriers, 11 MODY1 patients, 18 type 2 diabetes patients and 19 healthy control individuals. Subjects in the case-control study were recruited from the Botnia study or the Clinic of Endocrinology, Malmö University Hospital. Serum apoM levels were measured using a novel ELISA based on two monoclonal apoM antibodies.


RESULTS
In the family study, mean serum apoM was 10% lower in female carriers of the P291fsinsC mutation compared to the family controls (P = 0.0058), a difference which remained significant after adjustment for diabetes status. There was no observed difference between groups for men. In the case-control study, no significant difference in apoM concentration was observed between MODY3 and type 2 diabetes patients, neither before nor after adjustment for total cholesterol.


CONCLUSIONS
Female carriers of the P291fsinsC mutation in HNF-1alpha displayed slightly lower apoM serum levels. This difference is too small for apoM to be reliably employed as a biomarker for HNF-1alpha mutation status.
Cervin
C
C
Department of Clinical Sciences, Diabetes & Endocrinology, Clinical Research Centre, Malmö University Hospital, Lund University, Malmö, Sweden.
Axler
O
O
Holmkvist
J
J
Almgren
P
P
Rantala
E
E
Tuomi
T
T
Groop
L
L
Dahlbäck
B
B
Karlsson
E
E
D000328:Adult; D001053:Apolipoproteins / Q000097:blood*; D000075243:Apolipoproteins M; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000235:genetics; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D020022:Genetic Predisposition to Disease; D051538:Hepatocyte Nuclear Factor 1-alpha / Q000235:genetics; D006579:Heterozygote; D006801:Humans; D054834:Lipocalins; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011237:Predictive Value of Tests; D012737:Sex Factors
C400523:APOM protein, human; D001053:Apolipoproteins; D000075243:Apolipoproteins M; D015415:Biomarkers; D051538:Hepatocyte Nuclear Factor 1-alpha; D054834:Lipocalins